Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... and Robert Garcea, M.D., of the University of Colorado at Boulder. L2 prophylactic HPV vaccine. Testing continues for an agent that targets an HPV protein called L2 and is ... The grant will focus on next-generation human papillomavirus (HPV) vaccines for the prevention of cervical cancer and test more therapeutic agents that have shown ...
2009 NOV 23 ... a privately held biotechnology company focused on the development of therapeutic and prophylactic vaccines based on proprietary recombinant strains of the bacterium Listeria monocytogenes, ...
2009 OCT 12 ... of Defense. The FDA has designated Restanza as an orphan drug for the post-exposure prophylactic treatment of inhalation anthrax, plague and tularemia, but the FDA has not yet approved ... Tetracycline, Therapy, Treatment, Tularemia, U.S. Food and Drug Administration, Vaccines, Yersinia Pestis, Advanced Life Sciences Holdings Inc. This article was ...
2009 OCT 19 ... that treats human papilloma virus (HPV) related tumors. Unlike currently marketed prophylactic vaccines that require treatment prior to exposure to the virus, ADXS11-001 treats patients who ...
2009 SEP 28 ... Data detailed in 'Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant' have been presented. According ...
2009 NOV 23 ... E. Galani and colleagues, . The researchers concluded: "The development of prophylactic vaccines against human papilomavirus has been hailed as one of the most significant advances of ...
2009 NOV 24 ... "These data highlight the need for development and implementation of effective prophylactic measures, such as vaccines, to prevent the large burden of rotavirus disease among ...
2009 NOV 16 ... Flt3 ligand (Flt3L) expressed in B16 and coupled with CTLA-4 blockade promotes both prophylactic and therapeutic rejection of B16. When administered at the site of growing tumor, Gvax ... Curran and colleagues published their study in Cancer Research (Tumor Vaccines Expressing Flt3 Ligand Synergize with CTLA-4 Blockade to Reject Preimplanted Tumors. ...
2009 OCT 20 ... of scale." The study describes the players and prospects for a variety of prophylactic and therapeutic vaccines; the status of global initiatives to develop vaccines to combat ...
2009 NOV 9 ... Research, DNA Vaccines, HIV, Human Immunodeficiency Virus, Immunization, Medical Device, Prophylactic Vaccines, Prophylaxis, Vaccination, Virology. This article was prepared by AIDS ...
2009 NOV 16 ... INVANZ in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patients and increases the risk of the ... Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to ...
2009 OCT 5 ... diagnostic epitopes, and (3) protective B-cell epitopes for generating immuno-prophylactic antibodies. WRAIR/NMRC investigators bring to the effort their expert knowledge of DENV. ... DEEP™ peptide copolymer technology for the potential development of dengue vaccines and point-of-care diagnostics. After more than 70 years of work a safe and ...
2009 OCT 19 ... coupling the effective, long-term immunity elicited by the high-coverage MV vaccine to prophylactic HBV immunity are discussed." Valle and colleagues published their study in ... Keywords: United States, Rochester, Antigens, Biotechnology, Gastroenterology, HBV Vaccines, Hepatitis B Virus, Hepatology, Immunization, Infectious Disease, Measles, Vaccination, ...
2009 NOV 16 ... HPV 33 were the most prevalent HPV types in Beijing, indicating the potential for the prophylactic HPV 16/18 vaccine in China." Zhao and colleagues published their study in ... NY 10010-1707, USA. Keywords: People's Republic of China, Beijing, Cancer Vaccines, DNA, HPV, Human Papillomavirus, Immunization, Oncology, Women's Health. ...
2009 NOV 23 ... published their study in Cancer Prevention Research (A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against ... USA. Keywords: City:Copenhagen, Country:Denmark, Biotechnology, Cancer Vaccines, Clinical Trial Research, DNA, Gynecology, HPV Vaccines, Human Papillomavirus Vaccines, ...
2009 OCT 19 ... of a simian immunodeficiency virus (SIV) challenge in rhesus macaques. We developed a prophylactic vaccine by using a Sendai virus (SeV) vector expressing a single SIV Gag(241-249) CTL ... "Despite many efforts to develop AIDS vaccines eliciting virus-specific T-cell responses, whether induction of these memory T cells by ...
2009 NOV 3 ... has announced the addition of the "The 2009-2014 World Outlook for Prophylactic Vaccines" report to their offering. WHAT IS LATENT DEMAND AND THE P.I.E.? ...
2009 OCT 12 ... ADXS11-001 Immunotherapy ADXS11-001 is a therapeutic vaccine, unlike currently marketed prophylactic vaccines, that treats women who have already developed cervical cancer as a result of human ...
